Aspen Neuroscience Receives RMAT Designation for Parkinson's Therapy

Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company focused on personalized, autologous cell therapies, has announced that its lead investigational product, sasineprocel (ANPD001), for treating Parkinson's Disease (PD), has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA). The RMAT designation provides enhanced FDA guidance and expedited development support, which includes potential eligibility for priority review and accelerated approval pathways for regenerative therapies considered transformative. Aspen had previously received FDA Fast Track designation for sasineprocel, reinforcing its clinical potential, innovative iPSC-derived cell therapy platform, and the promise to alter the course of PD. The RMAT designation is based on findings from the ongoing Phase 1/2a ASPIRO trial*, which has shown encouraging early clinical activity and a favorable safety profile. The ASPIRO study is an open-label, multicohort, multicenter trial that assesses the safety, tolerability, and activity of surgically delivering autologous dopaminergic neuron precursor cells (DANPCs) into the putamen, the brain area where dopamine signaling restoration is essential. "This significant milestone highlights the transformative nature of sasineprocel as a potentially disease-modifying therapy for patients facing a serious disease with substantial unmet medical need," stated Damien McDevitt, Ph.D., president and chief executive officer of Aspen Neuroscience. "We stand with the Parkinson's community realizing the urgency around the serious and growing unmet need in PD and are unwavering in our commitment to bring sasineprocel to patients as soon as possible." Ana Sousa, chief regulatory officer, added, "FDA has created this collaborative regulatory framework to facilitate early and frequent interactions, align on development requirements, and potentially support more efficient pathways to approval." She emphasized that the team is diligently working to advance this investigational therapy aimed at regenerating neural networks and restoring lost neuronal function, with the goal of improving motor function, enhancing quality of life, and reversing disease progression for patients. The RMAT designation was established under the 21st Century Cures Act to expedite the development and review of regenerative medicine therapies intended to treat, modify, reverse, or cure serious conditions. To qualify, a product must demonstrate preliminary clinical evidence indicating its potential to meet unmet medical needs. RMAT designation provides sponsors with advantages such as early and frequent FDA interactions, potential eligibility for priority review, and potential accelerated approval. Aspen Neuroscience is at the forefront of developing autologous induced pluripotent stem cell-derived (iPSC) therapies, starting with neurodegenerative diseases with high unmet needs, including PD. Sasineprocel is a single-dose, autologous iPSC-based cell therapy currently under evaluation for PD treatment. The company believes that sasineprocel has the potential to be disease-modifying by replacing a patient's lost dopaminergic (DA) neurons with DANPCs, aiming to reconstruct the neural circuitry lost during disease progression. Sasineprocel is derived from a patient's own cells through a small skin punch biopsy, which are then reprogrammed to iPSCs and differentiated into DANPCs. The proprietary cell composition is delivered via image-guided administration to the putamen, the brain area crucial for dopamine signaling restoration. This method is designed to create a biologically active cellular microenvironment that promotes engraftment, survival, and functional integration of the transplanted cells, ultimately aiming to achieve lasting clinical benefits for PD patients and potentially slow or halt disease progression. As it utilizes the patient's own cells, sasineprocel eliminates the need for immunosuppression that is typically required for donor-derived (allogeneic) cell therapies. For more information, visit www.aspenneuroscience.com. *Funding for Cohorts 1 and 2 provided by the California Institute for Regenerative Medicine (CIRM), a state agency that supports regenerative medicine, stem cell, and gene therapy research.